PMID- 16758651
OWN - NLM
STAT- MEDLINE
DCOM- 20060622
LR  - 20191110
IS  - 1098-3597 (Print)
IS  - 1873-4480 (Linking)
VI  - 7
IP  - 4
DP  - 2005
TI  - Pharmacologic therapy for the management of thrombosis: unfractionated heparin or 
      low-molecular-weight heparin?
PG  - 39-48
AB  - Heparin and heparin-derived drugs play a major therapeutic role in thrombotic and 
      cardiovascular disorders. Infusion of unfractionated heparin (UFH) followed by 
      warfarin has traditionally been the standard pharmacologic therapy for treatment 
      of venous thromboembolism (VTE), which includes both deep vein thrombosis and 
      pulmonary embolism, and for initial therapy of non-ST-elevation (NSTE) acute 
      coronary syndrome (ACS). More recently, low-molecular-weight heparins (LMWHs) 
      have been shown to provide at least as good efficacy and safety outcomes as UFH 
      regimens for prevention of these conditions. In addition to good efficacy 
      outcomes with LMWHs compared with UFH, LMWHs have other advantages over UFH, 
      including improved bioavailability, QD administration, more predictable 
      anticoagulant response, lack of the need for monitoring, and suitability for 
      outpatient use, thereby increasing convenience, reducing cost, and improving 
      cost-to-benefit ratios. In carefully screened and managed patients, LMWH offers a 
      cost-effective, convenient, and safe alternative to UFH for thrombosis 
      management. The aim of this article is to summarize efficacy, safety, and 
      pharmacoeconomic considerations when selecting LMWH versus UFH for thrombosis 
      management in VTE and NSTE ACS.
FAU - Spyropoulos, Alex C
AU  - Spyropoulos AC
AD  - Clinical Thrombosis Center, Lovelace Sandia Health Systems, Albuquerque, New 
      Mexico 87108, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Clin Cornerstone
JT  - Clinical cornerstone
JID - 9816002
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Ambulatory Care/methods
MH  - Anticoagulants/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - Postoperative Complications/drug therapy/*prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Thromboembolism/*prevention & control
MH  - Venous Thrombosis/drug therapy/prevention & control
RF  - 27
EDAT- 2006/06/09 09:00
MHDA- 2006/06/23 09:00
CRDT- 2006/06/09 09:00
PHST- 2006/06/09 09:00 [pubmed]
PHST- 2006/06/23 09:00 [medline]
PHST- 2006/06/09 09:00 [entrez]
AID - S1098-3597(05)80102-4 [pii]
AID - 10.1016/s1098-3597(05)80102-4 [doi]
PST - ppublish
SO  - Clin Cornerstone. 2005;7(4):39-48. doi: 10.1016/s1098-3597(05)80102-4.